Name of journal: World Journal of Cardiology

ESPS Manuscript NO: 16733

Columns: Minireviews

Prognostic impact of atrial fibrillation on clinical outcomes of acute coronary syndromes, heart failure and chronic kidney disease

Patel NJ *et al.* Impact of atrial fibrillation on outcomes

Nileshkumar J Patel, Aashay Patel, Kanishk Agnihotri, Dhaval Pau, Samir Patel, Badal Thakkar, Nikhil Nalluri, Deepak Asti, Ritesh Kanotra, Sabeeda Kadavath, Shilpkumar Arora, Nilay Patel, Achint Patel, Azfar Sheikh, Neil Patel, Apurva O Badheka, Abhishek Deshmukh, Hakan Paydak, Juan Viles-Gonzalez

**Nilesh Kumar J Patel, Dhaval Pau, Nikhil Nalluri, Deepak Asti, Ritesh Kanotra, Azfar Sheikh**, Cardiovascular Division, Staten Island University Hospital, Staten Island, NY 10305, United States

**Aashay Patel**, Cardiovascular Division, Lankenau Institute of Medical Research, Wynnewood, PA 19096, United States

**Kanishk Agnihotri, Nilay Patel**, Cardiovascular Division, Saint Peters University Hospital, New Brunswick, NJ 08901, United States

**Samir Patel**, Cardiovascular Division, Western Reserve Health Education, Yougstown, OH 44504, United States

**Badal Thakkar**, Cardiovascular Division, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA 70112, United States

**Sabeeda Kadavath**, Cardiovascular Division, Lincoln Medical and Mental Health Center, Bronx, NY 10451, United States

**Shilpkumar Arora**, Cardiovascular Division, St. Lukes Roosevelt Hospital, New York, NY 10025, United States

**Achint Patel, Neil Patel**, Cardiovascular Division, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States

**Apurva O Badheka**, Cardiovascular Division, Yale School of Medicine, New Haven, CT 06519, United States

**Abhishek Deshmukh**, Cardiovascular Division, Mayo Clinic, Rochester, MN 55905, United States

**Hakan Paydak**, Cardiovascular Division, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States

**Juan Viles-Gonzalez**, Cardiovascular Division, University of Miami Miller School of Medicine, Miami, FL 33136, United States

**Author contributions:** All authors have contributed significantly to the effort of conducting this article; Patel NJ, Patel A, Agnihotri K and Pau D contributed equally to the conception of this article and to the final content of this manuscript; all other authors have contributed to the drafting of the manuscript.

**Conflict-of-interest:** All authors have no disclosures or conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to: Nileshkumar J Patel, MD,** Cardiovascular Disease, Staten Island University Hospital, 475 Seaview Avenue, Staten Island, NY 10305, United States. dr.nilesh.j.patel@gmail.com

**Telephone:** +1-201-7449111

**Fax:** +1-610-3941787

**Received:** January 28, 2015

**Peer-review started:** January 28, 2015

**First decision:** March 6, 2015

**Revised:** April 6, 2015

**Accepted:** April 28, 2015

**Article in press:**

**Published online:**

# Abstract

# Atrial fibrillation (AF) is the most common type of sustained arrhythmia, which is now on course to reach epidemic proportions in the elderly population. AF is a commonly encountered comorbidity in patients with cardiac and major non-cardiac diseases. Morbidity and mortality associated with AF makes it major health care burden. Objective of our article is to see a role of AF on prognostic impact of acute coronary syndromes, heart failure and chronic kidney disease. Multiple studies have been conducted to determine if AF has an independent role in the overall mortality of such patients. Our review suggests that atrial fibrillation has an independent adverse prognostic impact on the clinical outcomes of acute coronary syndromes, heart failure and chronic kidney disease.

**Key words:** Atrial fibrillation; Acute coronary syndromes; Heart failure; Chronic kidney disease; Prognostic impact

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

# Core tip: Atrial fibrillation (AF), the most common type of arrhythmia, is on course to reach epidemic proportions in the elderly. AF is a commonly encountered comorbidity in patients with acute coronary syndromes, heart failure and chronic kidney disease. Multiple studies have been conducted to determine if AF has an independent role in the overall mortality of such patients. Our review suggests that atrial fibrillation has an independent adverse prognostic impact on the clinical outcomes of acute coronary syndromes, heart failure and chronic kidney disease.

Patel NJ, Patel A, Agnihotri K, Pau D, Patel S, Thakkar B, Nalluri N, Asti D, Kanotra R, Kadavath S, Arora S, Patel N, Patel A, Sheikh A, Patel N, Badheka AO, Deshmukh A, Paydak H, Viles-Gonzalez J. Prognostic impact of atrial fibrillation on clinical outcomes of acute coronary syndromes, heart failure and chronic kidney disease. *World J Cardiol* 2015; In press

**INTRODUCTION**

Atrial fibrillation is a commonly encountered arrhythmia in clinical practice[1] with an increased prevalence being reported with advanced age[2]. It is estimated that more than 8 million patients over the age of 80 will be affected by the year 2050[1,3]. Consequently, the associated healthcare expenses are also rising and have reached an all-time high of 16 to 26 billion dollars annually[4]. The major contributors to the burgeoning healthcare costs of AF include outpatient care and testing which accounted for nearly $1.5 billion of the total costs, prescription drugs that cost an approximate of $235 million, and also high costs associated with inpatient interventional procedures[4-6].

With a rising prevalence and economic burden, there is concern in the medical community regarding the temporal effect of cardiovascular conditions including atrial fibrillation on the clinical outcomes of associated comorbidities. In addition to its deleterious health consequences, cardiovascular disease is number one cause of death in United States and globally[7]. It is important to understand role of other comorbidities in cardiovascular disease to prevent and reduce this mortality. In this article we focus on atrial fibrillation and common associated comorbidities. Atrial fibrillation is commonly encountered in the setting of acute coronary syndromes, heart failure and chronic kidney disease. The purpose of this article is to review the prognostic impact of atrial fibrillation on these co morbid conditions.

**ACUTE CORONARY SYNDROMES**

Acute coronary syndrome (ACS) is commonly associated with concomitant or incident AF. Most of the studies conducted have noted that the incidence of AF in ACS ranges from 2.3% to 23%[8]. Multiple factors explain this wide range of variation. The Cooperative Cardiovascular Project by Rathore *et al*[9] reported a higher incidence of AF in ACS patients, as the subjects were primarily elderly patients. Eldar *et al*[10] reported a lower incidence as they studied only paroxysmal AF. Some randomized controlled trials like TRACE and OPTIMAAL which studied the efficacy of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) in acute myocardial infarction (AMI) have also reported lower incidences, the efficacy of these drugs in preventing atrial fibrillation had however been proven in earlier studies[11,12].

Broadly there has been a downward trend in the incidence of AF in AMI in studies done over time. This can be explained possibly by more widespread use of thrombolytic therapy and percutaneous coronary interventions (PCI) over the years. Advanced age, tachycardia at the time of admission, and advanced stage of heart failure were found to be the major clinical predictors of atrial fibrillation in patients with AMI[9,13,14].

Early studies done to assess the independent prognostic impact of atrial fibrillation on ACS outcomes were found to have contrasting results. A number of studies after multivariate analyses found atrial fibrillation had no independent impact and concluded that it was more the coexisting comorbidities that contributed to the mortality[10,14-19]. However a greater number of studies reported atrial fibrillation in the setting of AMI to have worse prognostic outcome[9,11-13,19-22].

Two major meta-analyses done by Jabre *et al*[23] and Angeli *et al*[24] however proved conclusively the independent impact atrial fibrillation had on AMI. In the analysis of 43 studies by Jabre *et al*[23] where 278854 patients were studied, it was observed that AF was associated with a 40% increase in risk mortality as compared to patients with normal sinus rhythm. While the impact of atrial fibrillation on both in hospital mortality and long term mortality was noted, the timing of atrial fibrillation development, *i.e.*, new onset or pre-existing AF was not a contributor to the poor outcome as per this meta-analysis. Angeli *et al*[24], on the other hand, found that new onset atrial fibrillation had worse outcomes with an 87% higher risk compared to pre-existing atrial fibrillation. The study however only assessed in hospital mortality and not long-term outcomes.

Atrial fibrillation leads to a number of hemodynamic effects such as loss of atrial contraction, rapid ventricular rates, loss of atrio-ventricular synchrony and an irregular RR interval. All these factors lead to a decreased cardiac output, which in turn explain the higher mortality rates[25,26].

Many mechanisms have been proposed to explain how AF is commonly encountered in the setting of ACS. Although many theories exist, pathophysiological mechanism of the onset of AF after ACS is still not clearly understood. Conclusions drawn from experimental models and clinical investigations have shown different factors accounting for new-onset AF in ACS. It can be explained either by myocardial infarction causing atrial ischemia or atrial stretch[27]. Role of inflammation, autonomic nervous system activity, BNP and other hormone activation cannot be excluded as possible mechanisms for AF development in this patient subset[28,29]. Thus proper understanding of role of new onset AF complicating ACS can provide us with a new approach in formulating therapeutic guidelines.

Consensus has been reached on the independent role of AF on mortality in ACS. Treatment targeting the pathophysiological mechanism of AF development in ACS remains an area that needs to be explored. It therefore remains imperative to develop strategies to prevent AF onset and initiate aggressive treatment in case of a new onset AF in ACS.

**HEART FAILURE**

Heart failure (HF) and AF are closely linked cardiovascular diseases that often coexist and share a complex pathophysiological relationship. Both have continuously increasing prevalence, and the presence of AF in HF patients has been reported as being anywhere between 10% and 50%[30]. The difference in coexistence of this two-disease condition can be attributed to the different study settings, study design, severity of heart failure and other factors[30,31]. The prevalence of AF correlates directly with the severity of HF, as about 5% of patients with New York Heart Association (NYHA) class I HF have AF and this prevalence increases to about 50% in NYHA class IV HF[32,33]. Regardless of the study design, a few factors like hypertension, prior history of ACS, diabetes, and obesity were commonly observed to be associated with an increasing prevalence of AF and HF.

Recent large heart failure trials have demonstrated the adverse prognostic influence of AF on HF[34]. The study conducted by Dries *et al*[35], in which data obtained from SOLVD trial showed AF was associated with an increased risk of all cause mortality in patients with symptomatic and asymptomatic left ventricular systolic dysfunction[35]. On the other hand the COMET trial analysis by Swedberg *et al*[36] showed AF did increase mortality risk and HF hospitalizations but it was not identified as an independent risk factor for mortality when adjustment for other prognostic indicators was made[36].

AF also increases re-hospitalization rates, hospital stays, and has an overall adverse prognosis in HF patients that is very clearly evident in many studies. Mounantonakis *et al*[37] analyzed data obtained from 99810 patients enrolled in the Get with the guidelines- Heart failure Registry and concluded that AF independently was associated with adverse hospital outcomes and a longer length of in-hospital stay. Mentz *et al*[38] showed presence of AF on initial electrocardiogram in patients hospitalized with HF was associated with higher readmission, higher mortality and lower use of evidence-based therapies.

Corell *et al*[39] proved an adverse prognostic impact of AF in HF patients. Olsson *et al*[40] reviewed results from Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program and showed that AF is associated with an increased risk of poor cardiovascular outcomes. In the meta-analysis by Mamas *et al*[41] which included 16 studies involving 53969 patients; the conclusion was that irrespective of left ventricular systolic function, AF has an overall adverse prognosis in HF patients.

Pathophysiological changes that explain the increased prevalence of AF in HF patients are not very well understood. It is difficult to ascertain in most cases if HF leads to AF or changes due to AF leads to worsening of the underlying HF. Studies have different conclusions on the cause - effect process but there is a general agreement about the vicious cycle of deterioration when both conditions co-exist. According to one thought process, HF results in specific electrophysiological changes in the atrium like prolonging the atrial refractory period or increasing heterogeneity of repolarization that leads to the development of AF[42]. On the other hand, HF also plays a part in concurrent worsening of AF through mechanical and hemodynamic changes. Atrial tissue stretching occurs as a result of the increased pressure and volume in HF patients, which in turn triggers AF by increasing automaticity and altering atrial repolarization[43]. Activation of the renin-angiotensin system secondary to HF and other neurohormonal changes also promotes the development of AF[43]. Further studies need to be conducted to understand the impact AF has on HF, especially in regards to the dynamic pathophysiological interplay and therapy should be aimed at correcting the predisposing factors.

Although beyond the scope of this article, the optimal management approach of AF in HF remains unclear. Pharmacological therapy remains the mainstay of choice in AF, and includes rate control and rhythm control. A recent meta-analysis involving 2486 patients suggested no significant difference in terms of mortality and thromboembolic events between both modes of pharmacological management. However, hospitalizations appear to be less frequent with rate control than with rhythm control[44]. Also there are data that suggest role of cardiac resynchronization therapy (CRT) in non-ischemic dilated cardiomyopathy and severe heart failure, which has favorable outcome on incidence of AF[45,46]. In future further studies are warranted to determine the optimal management approach for AF in patients with HF.

**CHRONIC KIDNEY DISEASE**

It is a well-established fact that there is a high occurrence of cardiovascular disease in patients with chronic renal insufficiency. The overall prevalence of AF is higher among patients with end-stage renal disease (ESRD)[47]. Studies examining the prevalence of AF in cohorts pooled from the Dialysis Outcomes and Practice Patterns Study (DOPPS) and the United States Renal Data System (USRDS) estimated the occurrence of AF to range from 6% to 27% among patients with ESRD on dialysis[48-50]. This high rate of occurrence in ESRD patients is nearly two times higher than that reported in the general population[49]. Dissimilarity of the individual study pattern, study population, sample size, disease definition and diagnostic methods of AF can account for the difference between the prevalence of AF in this population.

Studies done by JB Wetmore *et al*[50] and V Wizeman *et al*[48] concluded that there exists a significantly higher prevalence of AF in ESRD patients on dialysis. On the other hand, recent studies have found a higher incidence and prevalence of AF among patients with CKD who have not been started on dialysis, as is clearly evident in the ARIC study and CRIC study done by Alonso *et al*[51] and Soliman *et al*[52]. In the latter study by Soliman *et al*[52] where a multicenter cohort with a wide range of kidney function was studied, it was estimated that the prevalence of AF was at 18%.

Moreover, AF is an independent risk factor for ischemic stroke and death among patients with ESRD on dialysis[53]. A large cross sectional cohort study conducted by Winkelmayer *et al*[49], analyzed data from 1992 to 2006 for the prevalence of AF in hemodialysis patients from the United States Renal Data System (USRDS). According to this study, the prevalence of AF increased 3 fold from 3.5% in 1992 to 10.7% in 2006. A one-year mortality rate among patients with AF was twice that of those without AF and was as high as 72% after demographic variant adjustment was made.

Several mechanisms have been proposed to explain the increased risk of death in CKD patients with AF. Promotion of systemic inflammation could be responsible for the fibrotic changes seen in the kidney and myocardium and by promoting worsening of cardiovascular outcomes such as heart failure, thromboembolic risk and stroke which in turn increases the risk of morbidity and mortality[35,54-57].

A large cohort study on adults with AF by Go *et al*[58] concluded that a lower level of GFR was associated with an increased risk of thromboembolism independent of the known AF risk factors. A higher rate of thromboembolic events was observed among individuals with a lower level of the estimated GFR.

The cumulative effect of AF and CKD together has been shown to not only increase mortality but also the rate of cardiovascular events, as has been observed in two separate studies done by Nakagawa *et al*[59] in Japan and Genovesi e*t al*[60] in Italy. From the findings of the study by Nakagawa *et al*[59], it was determined that a lower eGFR (< 60 mL/min per 1.73 m2) with CHADS2 score > 2 was associated with a higher all-cause (12.9% *vs* 1.4% per year, *P* < 0.001) and cardiovascular (6.5% *vs* 0.2% per year, *P* < 0.001) mortalities compared to preserved eGFR (> 60 mL/min per 1.73 m2) combined with CHADS2 score < 2. Also cardiovascular events, which include cardiac death, nonfatal myocardial infarction, or hospitalization for worsening of heart failure and ischemic stroke risk, were much higher in the same group (13.6% *vs* 1.5% per year, *P* < 0.001). The study concluded that a combined eGFR and CHADS2 score could be an independent powerful predictor of cardiovascular events and mortality in patients with nonvalvular AF[59].

Although there is a substantial increased risk of thromboembolism in patients with CKD and AF, there are no distinct guidelines to follow for thromboembolism prophylaxis in AF patients with CKD when compared to patients without CKD. Patients with severe renal impairment have been excluded from a vast majority of trials studying stroke prevention in AF, including trials that have formed the landmark for risk factor scoring schemes and guidelines. It therefore, poses a huge challenge to healthcare providers to treat this subset of patients. The available data suggests that the benefit from warfarin in terms of stroke reduction in CKD patients is not as clear as in the general population, and there is also an increased risk of bleeding complications[61].

One of the few studies that show a favorable outcome of anticoagulation for prevention of stroke in renal failure patients is the study by Hart *et al*[62]. Efficacy of adjusted-dose warfarin in prevention of stroke in atrial fibrillation patients with stage 3 CKD was demonstrated by this study. The study by Chan *et al*[63], a large retrospective cohort study of patients with AF on hemodialysis, suggests that warfarin use is associated with an increased risk for ischemic (HR, 1.81; 95%CI: 1.12-2.92) and hemorrhagic (HR, 2.22; 95%CI: 1.01-4.91) stroke. The data however is influenced by lack of appropriate monitoring and difficulties in maintaining the international normalized ratio (INR) target[63].

Thus, it remains a dilemma to refer to the benefits of warfarin administration as has been determined by anticoagulation guidelines in the general population, to a group of people that have been actively excluded from clinical trials; the prediction rules for bleeding risk would be inaccurate and oversimplified and probably not suitable for clinical practice. In reality, there appears to be no large randomized controlled trials that evaluate the real risk vs. benefit of full intensity anticoagulation including newer novel anticoagulants in patients with severe renal impairment. Information about management is limited and in the future there might be an opportunity to look into these patients and form risk stratification guidelines that can be followed.

**LIMITATIONS**

Although we have searched wide range of appropriate literature from online data source for our article, sometimes such studies are potentially susceptible to vary in conclusion due to different populations, settings, interventions, or outcome measures. All the studies we included have different limitations. Despite the limitations, the present article has important strengths, including a real-world large sample size from different studies and the absence of selection bias associated with clinical trials.

**CONCLUSION**

In conclusion, atrial fibrillation is a commonly encountered arrhythmia in clinical practice that has a rising prevalence and significant adverse prognostic implication on other comorbidities. In this article we concluded that AF with its rising prevalence increases the economic burden on healthcare and also has independent adverse prognostic impact on comorbidities like acute coronary syndromes, heart failure and chronic kidney disease. A thorough understanding of AF prevalence and better understanding of its pathophysiology including role of genetic component can serve as a potential biomarker for the prevention and treatment of AF in future[64,65]. Along with it, factors associated with AF and its increased association with other comorbidities, outcomes of these comorbidities in the setting of AF, prospective data and appropriate guidelines are needed to define more precisely how to treat these patients. Individual risk stratification may represent the best possible approach and provide opportunities for improvement in future. Further studies need to be conducted to determine risk stratification for decision making and to develop an optimal management approach.

**REFERENCES**

1 **Go AS**, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001; **285**: 2370-2375 [PMID: 11343485 DOI: 10.1001/jama.285.18.2370]

2 **Patel NJ**, Deshmukh A, Pant S, Singh V, Patel N, Arora S, Shah N, Chothani A, Savani GT, Mehta K, Parikh V, Rathod A, Badheka AO, Lafferty J, Kowalski M, Mehta JL, Mitrani RD, Viles-Gonzalez JF, Paydak H. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. *Circulation* 2014; **129**: 2371-2379 [PMID: 24842943 DOI: 10.1161/CIRCULATIONAHA.114.008201]

3 **Miyasaka Y**, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 2006; **114**: 119-125 [PMID: 16818816 DOI: 10.1161/CIRCULATIONAHA.105.595140]

4 **Kim MH**, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. *Circ Cardiovasc Qual Outcomes* 2011; **4**: 313-320 [PMID: 21540439 DOI: 10.1161/CIRCOUTCOMES.110.958165]

5 **Deshmukh A**, Patel NJ, Pant S, Shah N, Chothani A, Mehta K, Grover P, Singh V, Vallurupalli S, Savani GT, Badheka A, Tuliani T, Dabhadkar K, Dibu G, Reddy YM, Sewani A, Kowalski M, Mitrani R, Paydak H, Viles-Gonzalez JF. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. *Circulation* 2013; **128**: 2104-2112 [PMID: 24061087 DOI: 10.1161/CIRCULATIONAHA.113.003862]

6 **Badheka AO**, Chothani A, Mehta K, Patel NJ, Deshmukh A, Hoosien M, Shah N, Singh V, Grover P, Savani GT, Panaich SS, Rathod A, Patel N, Arora S, Bhalara V, Coffey JO, O'Neill W, Makkar R, Grines CL, Schreiber T, Di Biase L, Natale A, Viles-Gonzalez JF. Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States: influence of hospital volume. *Circ Arrhythm Electrophysiol* 2015; **8**: 42-48 [PMID: 25480543]

7 **Santulli G**. Epidemiology of Cardiovascular Disease in the 21st Century: Updated Numbers and Updated Facts. *JCvD* 2013; **1**: 1-2. Available from: URL: http: //researchpub.org/journal/jcvd/number/vol1-no1/vol1-no1-1.pdf

8 **González-Pacheco H**, Márquez MF, Arias-Mendoza A, Alvarez-Sangabriel A, Eid-Lidt G, González-Hermosillo A, Azar-Manzur F, Altamirano-Castillo A, Briseño-Cruz JL, García-Martínez A, Mendoza-García S, Martínez-Sánchez C. Clinical features and in-hospital mortality associated with different types of atrial fibrillation in patients with acute coronary syndrome with and without ST elevation. *J Cardiol* 2014; pii: S0914-5087(14)00327-X [PMID: 25480145 DOI: 10.1016/j.jjcc.2014.11.001]

9 **Rathore SS**, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ, Solomon AJ. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. *Circulation* 2000; **101**: 969-974 [PMID: 10704162 DOI: 10.1161/01.CIR.101.9.969]

10 **Eldar M**, Canetti M, Rotstein Z, Boyko V, Gottlieb S, Kaplinsky E, Behar S. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. *Circulation* 1998; **97**: 965-970 [PMID: 9529264 DOI: 10.1161/01.CIR.97.10.965]

11 **Pedersen OD**, Bagger H, Køber L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. *Eur Heart J* 1999; **20**: 748-754 [PMID: 10329066 DOI: 10.1053/euhj.1998.1352]

12 **Lehto M**, Snapinn S, Dickstein K, Swedberg K, Nieminen MS. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. *Eur Heart J* 2005; **26**: 350-356 [PMID: 15618041 DOI: 10.1093/eurheartj/ehi064]

13 **Crenshaw BS**, Ward SR, Granger CB, Stebbins AL, Topol EJ, Califf RM. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. *J Am Coll Cardiol* 1997; **30**: 406-413 [PMID: 9247512 DOI: 10.1016/S0735-1097(97)00194-0]

14 **Kinjo K**, Sato H, Sato H, Ohnishi Y, Hishida E, Nakatani D, Mizuno H, Fukunami M, Koretsune Y, Takeda H, Hori M. Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. *Am J Cardiol* 2003; **92**: 1150-1154 [PMID: 14609587 DOI: 10.1016/j.amjcard.2003.07.021]

15 **Asanin M**, Perunicic J, Mrdovic I, Matic M, Vujisic-Tesic B, Arandjelovic A, Vasiljevic Z, Ostojic M. Prognostic significance of new atrial fibrillation and its relation to heart failure following acute myocardial infarction. *Eur J Heart Fail* 2005; **7**: 671-676 [PMID: 15921810 DOI: 10.1016/j.ejheart.2004.07.018]

16 **Behar S**, Zahavi Z, Goldbourt U, Reicher-Reiss H. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group. *Eur Heart J* 1992; **13**: 45-50 [PMID: 1577030]

17 **Li K**, Huo Y, Ding YS. Clinical profile and outcomes of atrial fibrillation in elderly patients with acute myocardial infarction. *Chin Med J* (Engl) 2008; **121**: 2388-2391 [PMID: 19102954]

18 **Badheka AO**, Patel NJ, Grover PM, Shah N, Patel N, Singh V, Deshmukh AJ, Mehta K, Chothani A, Savani GT, Arora S, Rathod A, Marzouka GR, Lafferty J, Mehta JL, Mitrani RD. Optimal blood pressure in patients with atrial fibrillation (from the AFFIRM Trial). *Am J Cardiol* 2014; **114**: 727-736 [PMID: 25060415 DOI: 10.1016/j.amjcard.2014.06.002]

19 **Sakata K**, Kurihara H, Iwamori K, Maki A, Yoshino H, Yanagisawa A, Ishikawa K. Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction. *Am J Cardiol* 1997; **80**: 1522-1527 [PMID: 9416928 DOI: 10.1016/S0002-9149(97)00746-7]

20 **Mehta RH**, Dabbous OH, Granger CB, Kuznetsova P, Kline-Rogers EM, Anderson FA, Fox KA, Gore JM, Goldberg RJ, Eagle KA. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. *Am J Cardiol* 2003; **92**: 1031-1036 [PMID: 14583352 DOI: 10.1016/j.amjcard.2003.06.001]

21 **Pizzetti F**, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, Santoro L, Tognoni G. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. *Heart* 2001; **86**: 527-532 [PMID: 11602545 DOI: 10.1136/heart.86.5.527]

22 **Wong CK**, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. *Am Heart J* 2000; **140**: 878-885 [PMID: 11099991 DOI: 10.1067/mhj.2000.111108]

23 **Jabre P**, Roger VL, Murad MH, Chamberlain AM, Prokop L, Adnet F, Jouven X. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. *Circulation* 2011; **123**: 1587-1593 [PMID: 21464054 DOI: 10.1161/CIRCULATIONAHA.110.986661]

24 **Angeli F**, Reboldi G, Garofoli M, Ramundo E, Poltronieri C, Mazzotta G, Ambrosio G, Verdecchia P. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. *Curr Cardiol Rep* 2012; **14**: 601-610 [PMID: 22821004 DOI: 10.1007/s11886-012-0289-3]

25 **Clark DM**, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. *J Am Coll Cardiol* 1997; **30**: 1039-1045 [PMID: 9316536 DOI: 10.1016/S0735-1097(97)00254-4]

26 **Lubitz SA**, Benjamin EJ, Ellinor PT. Atrial fibrillation in congestive heart failure. *Heart Fail Clin* 2010; **6**: 187-200 [PMID: 20347787 DOI: 10.1016/j.hfc.2009.11.001]

27 **Ravelli F**, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. *Circulation* 1997; **96**: 1686-1695 [PMID: 9315565 DOI: 10.1161/01.CIR.96.5.1686]

28 **Psychari SN**, Apostolou TS, Sinos L, Hamodraka E, Liakos G, Kremastinos DT. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. *Am J Cardiol* 2005; **95**: 764-767 [PMID: 15757607 DOI: 10.1016/j.amjcard.2004.11.032]

29 **Bettoni M**, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. *Circulation* 2002; **105**: 2753-2759 [PMID: 12057990 DOI: 10.1161/01.CIR.0000018443.44005.D8]

30 **Fabbri G**, Maggioni AP. A review of the epidemiological profile of patients with atrial fibrillation and heart failure. *Expert Rev Cardiovasc Ther* 2012; **10**: 1133-1140 [PMID: 23098149 DOI: 10.1586/erc.12.110]

31 **Maisel WH**, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. *Am J Cardiol* 2003; **91**: 2D-8D [PMID: 12670636 DOI: 10.1016/S0002-9149(02)03373-8]

32 **SOLVD Investigators**. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. *N Engl J Med* 1992; **327**: 685-691 [PMID: 1463530 DOI: 10.1056/NEJM199209033271003]

33 **CONSENSUS Trial Study Group**. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. *N Engl J Med* 1987; **316**: 1429-1435 [PMID: 2883575 DOI: 10.1056/NEJM198706043162301]

34 **Anter E**, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. *Circulation* 2009; **119**: 2516-2525 [PMID: 19433768 DOI: 10.1161/CIRCULATIONAHA.108.821306]

35 **Dries DL**, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. *J Am Coll Cardiol* 1998; **32**: 695-703 [PMID: 9741514 DOI: 10.1016/S0735-1097(98)00297-6]

36 **Swedberg K**, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson P. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET. *Eur Heart J* 2005; **26**: 1303-1308 [PMID: 15767288]

37 **Mountantonakis SE**, Grau-Sepulveda MV, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. *Circ Heart Fail* 2012; **5**: 191-201 [PMID: 22361078 DOI: 10.1161/CIRCHEARTFAILURE.111.965681]

38 **Mentz RJ**, Chung MJ, Gheorghiade M, Pang PS, Kwasny MJ, Ambrosy AP, Vaduganathan M, O'Connor CM, Swedberg K, Zannad F, Konstam MA, Maggioni AP. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. *Am Heart J* 2012; **164**: 884-92.e2 [PMID: 23194489 DOI: 10.1016/j.ahj.2012.09.011]

39 **Corell P**, Gustafsson F, Schou M, Markenvard J, Nielsen T, Hildebrandt P. Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction. *Eur J Heart Fail* 2007; **9**: 258-265 [PMID: 17027330 DOI: 10.1016/j.ejheart.2006.08.004]

40 **Olsson LG**, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. *J Am Coll Cardiol* 2006; **47**: 1997-2004 [PMID: 16697316 DOI: 10.1016/j.jacc.2006.01.060]

41 **Mamas MA**, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. *Eur J Heart Fail* 2009; **11**: 676-683 [PMID: 19553398 DOI: 10.1093/eurjhf/hfp085]

42 **Nattel S**. Ionic determinants of atrial fibrillation and Ca2+ channel abnormalities: cause, consequence, or innocent bystander? *Circ Res* 1999; **85**: 473-476 [PMID: 10473677 DOI: 10.1161/01.RES.85.5.473]

43 **Van den Berg MP**, Tuinenburg AE, Crijns HJ, Van Gelder IC, Gosselink AT, Lie KI. Heart failure and atrial fibrillation: current concepts and controversies. *Heart* 1997; **77**: 309-313 [PMID: 9155607 DOI: 10.1136/hrt.77.4.309]

44 **Caldeira D**, David C, Sampaio C. Rate vs rhythm control in patients with atrial fibrillation and heart failure: a systematic review and meta-analysis of randomised controlled trials. *Eur J Intern Med* 2011; **22**: 448-455 [PMID: 21925051 DOI: 10.1016/j.ejim.2011.05.001]

45 **D'Ascia SL**, D'Ascia C, Marino V, Lombardi A, Santulli R, Chiariello M, Santulli G. Cardiac resynchronisation therapy response predicts occurrence of atrial fibrillation in non-ischaemic dilated cardiomyopathy. *Int J Clin Pract* 2011; **65**: 1149-1155 [PMID: 21995693 DOI: 10.1111/j.1742-1241.2011.02732.x]

46 **Santulli G**, D'ascia SL, D'ascia C. Development of atrial fibrillation in recipients of cardiac resynchronization therapy: the role of atrial reverse remodelling. *Can J Cardiol* 2012; **28**: 245.e17; author reply 245.e17-245.e18 [PMID: 22244772 DOI: 10.1016/j.cjca.2011.11.001]

47 **Bansal N**, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. *Circulation* 2013; **127**: 569-574 [PMID: 23275377 DOI: 10.1161/CIRCULATIONAHA.112.123992]

48 **Wizemann V**, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. *Kidney Int* 2010; **77**: 1098-1106 [PMID: 20054291 DOI: 10.1038/ki.2009.477]

49 **Winkelmayer WC**, Patrick AR, Liu J, Brookhart MA, Setoguchi S. The increasing prevalence of atrial fibrillation among hemodialysis patients. *J Am Soc Nephrol* 2011; **22**: 349-357 [PMID: 21233416 DOI: 10.1681/ASN.2010050459]

50 **Wetmore JB**, Mahnken JD, Rigler SK, Ellerbeck EF, Mukhopadhyay P, Spertus JA, Hou Q, Shireman TI. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. *Kidney Int* 2012; **81**: 469-476 [PMID: 22189842 DOI: 10.1038/ki.2011.416]

51 **Alonso A**, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, Soliman EZ, Astor BC, Coresh J. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 2011; **123**: 2946-2953 [PMID: 21646496 DOI: 10.1161/CIRCULATIONAHA.111.020982]

52 **Soliman EZ**, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, Ojo A, Teal VL, Jensvold NG, Robinson NL, Dries DL, Bazzano L, Mohler ER, Wright JT, Feldman HI. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). *Am Heart J* 2010; **159**: 1102-1107 [PMID: 20569726 DOI: 10.1016/j.ahj.2010.03.027]

53 **Sánchez-Perales C**, Vázquez E, García-Cortés MJ, Borrego J, Polaina M, Gutiérrez CP, Lozano C, Liébana A. Ischaemic stroke in incident dialysis patients. *Nephrol Dial Transplant* 2010; **25**: 3343-3348 [PMID: 20466665 DOI: 10.1093/ndt/gfq220]

54 **Chung MK**, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. *Circulation* 2001; **104**: 2886-2891 [PMID: 11739301 DOI: 10.1161/hc4901.101760]

55 **Hatzinikolaou-Kotsakou E**, Tziakas D, Hotidis A, Stakos D, Floros D, Papanas N, Chalikias G, Maltezos E, Hatseras DI. Relation of C-reactive protein to the first onset and the recurrence rate in lone atrial fibrillation. *Am J Cardiol* 2006; **97**: 659-661 [PMID: 16490433 DOI: 10.1016/j.amjcard.2005.09.104]

56 **Chen SC**, Su HM, Hung CC, Chang JM, Liu WC, Tsai JC, Lin MY, Hwang SJ, Chen HC. Echocardiographic parameters are independently associated with rate of renal function decline and progression to dialysis in patients with chronic kidney disease. *Clin J Am Soc Nephrol* 2011; **6**: 2750-2758 [PMID: 21980185 DOI: 10.2215/CJN.04660511]

57 **Wolf PA**, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. *Arch Intern Med* 1987; **147**: 1561-1564 [PMID: 3632164 DOI: 10.1001/archinte.1987.00370090041008]

58 **Go AS**, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, Singer DE. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. *Circulation* 2009; **119**: 1363-1369 [PMID: 19255343 DOI: 10.1161/CIRCULATIONAHA.108.816082]

59 **Nakagawa K**, Hirai T, Takashima S, Fukuda N, Ohara K, Sasahara E, Taguchi Y, Dougu N, Nozawa T, Tanaka K, Inoue H. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. *Am J Cardiol* 2011; **107**: 912-916 [PMID: 21247518 DOI: 10.1016/j.amjcard.2010.10.074]

60 **Genovesi S**, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, Valsecchi MG. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. *Am J Kidney Dis* 2008; **51**: 255-262 [PMID: 18215703 DOI: 10.1053/j.ajkd.2007]

61 **Ahmad Y**, Lip GY. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation. *Contrib Nephrol* 2013; **179**: 81-91 [PMID: 23652451 DOI: 10.1159/000346726]

62 **Hart RG**, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. *Clin J Am Soc Nephrol* 2011; **6**: 2599-2604 [PMID: 21903982 DOI: 10.2215/CJN.02400311]

63 **Chan KE**, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. *J Am Soc Nephrol* 2009; **20**: 2223-2233 [PMID: 19713308 DOI: 10.1681/ASN.2009030319]

64 **Santulli G**, Iaccarino G, De Luca N, Trimarco B, Condorelli G. Atrial fibrillation and microRNAs. *Front Physiol* 2014; **5**: 15 [PMID: 24478726 DOI: 10.3389/fphys.2014.00015]

65 **Wronska A**, Kurkowska-Jastrzebska I, Santulli G. Application of microRNAs in diagnosis and treatment of cardiovascular disease. *Acta Physiol* (Oxf) 2015; **213**: 60-83 [PMID: 25362848 DOI: 10.1111/apha.12416]

**P-Reviewer:** Aizawa Y, Ilgenli TF, Santulli G **S-Editor:** Ji FF **L-Editor: E-Editor:**